Tall cell variant papillary thyroid carcinoma in Saudi patients

References

1. ↵
   1. Wang X,
   2. Cheng W,
   3. Liu C,
   4. Li J

   (2016) Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget.
2. ↵
   1. Axelsson TA,
   2. Hrafnkelsson J,
   3. Olafsdottir EJ,
   4. Jonasson JG

   (2015) Tall cell variant of papillary thyroid carcinoma: a population-based study in Icel and Thyroid, 25:216–220.
3. ↵
   1. Solomon A,
   2. Gupta PK,
   3. LiVolsi VA,
   4. Baloch ZW

   (2002) Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol 27:143–148.

   OpenUrlCrossRefPubMed
4. ↵
   1. DeLellis RA LR,
   2. Heitz PU,
   3. Eng C

   (2004) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs (IARC Press, Lyon), pp 57–66.
5. ↵
   1. Lam AK,
   2. Lo CY,
   3. Lam KS

   (2005) Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol 16:323–330.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Ghossein R,
   2. Livolsi VA

   (2008) Papillary thyroid carcinoma tall cell variant. Thyroid 18:1179–1181.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Leung AK,
   2. Chow SM,
   3. Law SC

   (2008) Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 118:32–38.

   OpenUrlCrossRefPubMed
8. ↵
   1. Guan H,
   2. Vandenbussche CJ,
   3. Erozan YS,
   4. Rosenthal DL,
   5. Tatsas AD,
   6. Olson MT,
   7. et al.

   (2013) Can the tall cell variant of papillary thyroid carcinoma be distinguished from the conventional type in fine needle aspirates?A cytomorphologic study with assessment of diagnostic accuracy. Acta Cytol 57:534–542.

   OpenUrl
9. ↵
   1. Okuyucu K,
   2. Alagoz E,
   3. Arslan N,
   4. Emer O,
   5. Ince S,
   6. Deveci S,
   7. et al.

   (2015) Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma. Nucl Med Commun 36:1021–1025.

   OpenUrl
10. ↵
    1. LiVolsi VA

    (2010) Papillary carcinoma tall cell variant (TCV): a review. Endocrine pathology 21:12–15.

    OpenUrlCrossRefPubMed
11. ↵
    1. Kazaure HS,
    2. Roman SA,
    3. Sosa JA

    (2012) Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19:1874–1880.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Regalbuto C,
    2. Malandrino P,
    3. Frasca F,
    4. Pellegriti G,
    5. Le Moli R,
    6. Vigneri R,
    7. et al.

    (2013) The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. J Endocrinol Invest 36:249–254.

    OpenUrl
13. ↵
    1. Michels JJ,
    2. Jacques M,
    3. Henry-Amar M,
    4. Bardet S

    (2007) Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 38:212–219.

    OpenUrlCrossRefPubMed
14. ↵
    1. Roman S,
    2. Sosa JA

    (2013) Aggressive variants of papillary thyroid cancer. Curr Opin Oncol 25:33–38.

    OpenUrlPubMed
15. ↵
    1. Barbu CG,
    2. Florin A,
    3. Neamtu MC,
    4. Avramescu ET,
    5. Terzea D,
    6. Miron A,
    7. et al.

    (2015) Papillary thyroid carcinoma with anaplastic dedifferentiation in the lymph node metastasis - a rare form of presentation even for a tall cell variant. Rom J Morphol Embryol 56:527–531.

    OpenUrl
16. ↵
    1. Jalisi S,
    2. Ainsworth T,
    3. Lavalley M

    (2010) Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis. J Thyroid Res 2010:325602.

    OpenUrlCrossRefPubMed
17. ↵
    1. Basolo F,
    2. Torregrossa L,
    3. Giannini R,
    4. Miccoli M,
    5. Lupi C,
    6. Sensi E,
    7. et al.

    (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197–4205.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Gherardi E,
    2. Birchmeier W,
    3. Birchmeier C,
    4. Vande Woude G

    (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Nikiforov YE

    (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3–16.

    OpenUrlCrossRefPubMedWeb of Science